Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.

To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion.
A prospective, non-comparative, consecutive, interventional case series of 34 patients. Patients received repeated intravitreal injections of 1.25 mg bevacizumab. Main outcome measures were VA (Snellen charts and ETDRS) and retinal thickness (optical coherence tomography measurements) in a follow-up period of 6 months.
Patients presented at a mean age of 69 years (range 44-86). Mean duration of symptoms was 40 weeks (range 1-300). Mean (SD) VA at baseline was 0.79 (0.39) logMAR, improving to 0.51 (0.34) logMAR at 6 months (p = 0.009). Mean number of letters on the ETDRS chart at baseline was 45.3 (19.0), improving to 60.6 (19.9) at 6 months (p = 0.003). Mean (SD) retinal thickness at baseline was 474 (120) microm, declining to 316 (41) microm at 6 months.
Intravitreal injection of 1.25 mg bevacizumb appears to be an effective treatment option for branch retinal vein occlusion.
AuthorsT C Kreutzer, C S Alge, A H Wolf, D Kook, J Burger, R Strauss, C Kunze, C Haritoglou, A Kampik, S Priglinger
JournalThe British journal of ophthalmology (Br J Ophthalmol) Vol. 92 Issue 3 Pg. 351-5 (Mar 2008) ISSN: 1468-2079 [Electronic] England
PMID18211925 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors (administration & dosage, therapeutic use)
  • Antibodies, Monoclonal (administration & dosage, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Drug Administration Schedule
  • Female
  • Fovea Centralis (pathology)
  • Humans
  • Injections
  • Macular Edema (drug therapy, etiology, pathology, physiopathology)
  • Male
  • Middle Aged
  • Retinal Vein Occlusion (complications, pathology, physiopathology)
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)
  • Visual Acuity (drug effects)
  • Vitreous Body

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: